Drug-resistant Tuberculosis
Infectious Diseases
0
Pipeline Programs
2
Companies
1
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Heidelberg PharmaGermany - Ladenburg
1 programTargeted next-generation sequencingN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2024
2025
2026
2027
Heidelberg PharmaTargeted next-generation sequencing
Clinical Trials (1)
Total enrollment: 2,500 patients across 1 trials
Pragmatic Use of Next-generation Sequencing for Management of Drug-resistant Tuberculosis
Start: Aug 2024Est. completion: Jan 20272,500 patients
N/ARecruiting
Related Jobs in Infectious Diseases
Director, Program Management
Metaphore Biotechnologies
Somerville, MA USA
9h ago
$179K - $237K/yr
Consultor Técnico Vacinas Adulto (Brasília/DF)
GSK
BRA - Distrito Federal - Brasília
22h ago
Production Supervisor/First Line Leader
GSK
USA - North Carolina - Zebulon
22h ago
Community Engagement Account Manager - New Haven
GSK
USA - Connecticut - New Haven
22h ago
Scientist, Protein Purification
GSK
USA - Massachusetts - Cambridge
22h ago
$90K - $150K/yr
Scientist, Protein Biochemistry
GSK
USA - Massachusetts - Cambridge
22h ago
$90K - $150K/yr
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 2,500 patients
2 companies competing in this space